Shanghai Medicilon Inc.

  On the one hand, the burden on the eyes brought by electronic products has increased, and on the other hand, the eye health awareness of "seeing clearly and comfortably" has been improved.  High Growth, High Barriers, and High Prosperity Chinese ophthalmic drugs are rising explosively! The number of ophthalmology patients in China far exceeds that of the United States, reaching 1 billion, but the ophthalmic drug market is less than one-fifth of that of the United States.  In China's ophthalmic drug market, which started relatively late, the understanding of the pathogenesis of ophthalmic diseases is relatively lagging behind, and the innovative R&D capabilities are relatively weak.  It can be said that independent research and development of ophthalmic drugs is destined to be a road of groping in the dark.  On this road, Raymon Pharma is constantly moving forward with the lights on, exploring the dream of light. In March 2023, the eye drops RA1115-B1 self-...

  Recently, Raymon Pharma announced that the clinical trial of self-developed RA1115-B1 eye drops for the treatment of neovascular (wet) age-related macular degeneration (wAMD) was launched in China.  The Phase I clinical trial at Peking Union Medical College Hospital of the Academy of Medical Sciences, chaired by the principal investigators Professor Youxin Chen and Associate Professor Rui Che, has been completed with positive results. In the research and development of RA1115-B1 eye drops, Shanghai Medicilon Inc. (Medicilon) provided pharmaceutical research services such as raw material drug production, raw material drug process development, and preparation prescription process development to accelerate the R&D process. The first eye drops for the treatment of wAMD in China The therapeutic potential of RA1115-B1 is initially shown Wet age-related macular degeneration is a vision killer for middle-aged and elderly people.  Among the irreversible blinding eye diseases...